Nimenrix

Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid; Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid · Pfizer Europe MA EEIG

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Nimenrix, covering 2018-07-03 to 2025-02-13. Get the full timeline:

Most recent: EMA Authorised: Nimenrix (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid) — Pfizer Europe MA EEIG

See pricing